Over the last decade, my focus has been directed towards researching treatments for a variety of the most common psychiatric disorders – Depression, Anxiety, and various Mood Disorders. My treatment philosophy recognizes that pharmacological therapies for these conditions, should be aimed at an individual's particular genetic makeup. In my experience, when this approach is used in combination with transcranial magnetic stimulation, you find patients achieving higher rates of remission for longer periods of time.
Gregory Q. Marsella is a physician by training and a board-certified psychiatrist, who received his B.A. at Harvard, his M.D. at the University of Pennsylvania, and his residency training in psychiatry at New York Hospital-Cornell Medical Center. He is a practicing psychiatrist and psychopharmacologist.
Dr. Marsella is a co-founder of Da Vinci Research Institute, a small, independent clinical research company that does grant-based medical research and also offers local, contract research services to Fortune 500 pharmaceutical companies, biotechnology companies, and national CRO's. In addition to its other missions Da Vinci Research Institute is a medical research network furnishing study-procural, patient-recruitment, site-management, and research administrative services for its participating practices in Florida. Dr. Marsella has been a site investigator for Phase II, III, and IV multicenter, nationwide clinical trials, and has also authored and implemented grant-based medical research studies in child and adult psychopharmacology, neurology, epilepsy medicine, and pain-management.
SHORT SAMPLE OF PHASE II-IV MULTICENTER TRIALS, AND INVESTIGATOR-AUTHORED, GRANT-SUBSIDIZED RESEARCH, IN WHICH DR. MARSELLA WAS A PRINCIPAL INVESTIGATOR
1. "A Placebo-Controlled Study of Olanzapine in the Treatment of Bipolar I Depression." (Eli Lilly) 2. "An Open-Label Evaluation of Lamotrigine Versus Carbamapezine, Phenytoin, and Divalproex Sodium as Monotherapy for Epilepsy Patients Who Have Failed a Previous Course of AED Therapy." (GlaxoSmithKline) 3. "A 6-Month, Multi-Center, Placebo-Controlled, Chronic Migraine Treatment Trial with Topamax and either Propranolol or Placebo." (NIH/National Institute of Neurological Disorders and Stroke) 4. "Risperidone in the Treatment of Children with Autism Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety." (Johnson & Johnson) 5. "A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial of Varenicline for Cognitive Impairment in Subjects with Schizophrenia." (Pfizer)